pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Tagrisso
drug · small molecule
save

osimertinib mesylate

Marketedupdated 6mo ago
by $AZN ASTRAZENECA PLC🔗 ChEMBL
Approved
annual revenue · 2024–2024peak $6.6B
2024: $6.6B2024$6.6B
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and 1 investigational indication.

indications

investigational
NSCLC

targets

Epidermal growth factor receptor

all catalysts(0)

nothing on the calendar yet

Trials studying osimertinib mesylate

  • phase2A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLCrecruitingn=48
  • phase1Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancercompletedn=78
  • phase3A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastasesrecruitingn=380
  • phase2A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancerrecruitingn=300
  • phase1A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patientsactive not recruitingn=80
  • phase2A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Canceractive not recruitingn=198
  • phase2A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancerrecruitingn=40
  • phase2A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumorsrecruitingn=400

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 16, 2027
91 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

  • Nov 26, 2042method-of-use (U-3823)US 12465608
  • Nov 26, 2042method-of-use (U-3823)US 12465608
  • Jan 2, 2035formulationUS 10183020
  • Jan 2, 2035formulationUS 10183020
  • Aug 8, 2032compositionUS 8946235
  • Aug 8, 2032compositionUS 8946235
  • Jul 25, 2032compositionUS 11524951
  • Jul 25, 2032compositionUS 11524951
  • Jul 25, 2032compositionUS 9732058
  • Jul 25, 2032compositionUS 9732058

FDA exclusivities (6)

  • Dec 18, 2027ODE-337Orphan Drug (7y)1.1y
  • Dec 18, 2027ODE-337Orphan Drug (7y)1.1y
  • Sep 25, 2027I-952Indication (3y)312d
  • Sep 25, 2027I-952Indication (3y)312d
  • Feb 16, 2027I-941Indication (3y)91d
  • Feb 16, 2027I-941Indication (3y)91d

News(10)

  • AstraZeneca employs $1.5B cost savings to reinvest back into growth
    “You don't spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings.
    biospace · 17d ago
  • #ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer
    MADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it seems that th…
    endpoints · 21d ago
  • #ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
    MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep taking Tagrisso even after they have become resistant to the EGFR-targeting ty…
    endpoints · 22d ago
  • Pharma’s $500B patent problem will come in waves — not as a cliff
    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
    biopharma_dive · 1mo ago
  • ArriVent sheds nearly half of value on late-stage lung cancer miss
    ArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine…
    biospace · 1mo ago
  • Rare EGFR mutation increases lung cancer risk 62 times in never smokers
    A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.
    fiercebiotech · 2mo ago
  • WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
    The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
    biopharma_dive · 2mo ago
  • Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
    Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…
    fiercebiotech · 2mo ago
  • GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
    GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.
    fiercebiotech · 2mo ago
  • AstraZeneca scores in lung cancer; Sandoz inks a China deal
    A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
    biopharma_dive · 3mo ago
view all news mentions →
brand
Tagrisso
trade names
Tagrisso
generic
osimertinib mesylate
MOA
Epidermal growth factor receptor erbB1 inhibitor
indication
Non-Small Cell Lung Cancer
phase
marketed
approved
2015-11-13
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?